Drug news & perspectives最新文献_第5页

FtsZ inhibition: a promising approach for antistaphylococcal therapy. 抑制FtsZ:一种很有前途的抗葡萄球菌治疗方法。

Drug news & perspectives Pub Date : 2010-06-01 DOI: 10.1358/dnp.2010.23.5.1429489

Parminder Singh, Dulal Panda

{"title":"FtsZ inhibition: a promising approach for antistaphylococcal therapy.","authors":"Parminder Singh, Dulal Panda","doi":"10.1358/dnp.2010.23.5.1429489","DOIUrl":"https://doi.org/10.1358/dnp.2010.23.5.1429489","url":null,"abstract":"Staphylococcus causes a large number of animal and human diseases and has been considered as a major health concern. With the emergence of resistant strains of staphylococcus, like methicillin-resistant Staphylococcus aureus and vancomycin-resistant Staphylococcus aureus, the search for novel antibacterial targets has intensified. FtsZ, a bacterial cytoskeleton protein, is involved in cell division. FtsZ assembles into protofilaments in a GTP-dependent manner, and forms a dynamic Z-ring at the mid-cell position. The assembly dynamics of FtsZ in the Z-ring are regulated by the combined actions of several FtsZ-associated proteins. Furthermore, the interaction of FtsZ with accessory proteins is essential for their recruitment to the Zring. A disruption of this interaction perturbs the Z-ring formation. FtsZ inhibitors like PC-190723 have been suggested to inhibit the Staphylococcus cell division by perturbing the assembly and stability of FtsZ polymers. In this review, we discuss the assembly dynamics of Z-ring and its role in cell division. In addition, we highlight recent advances suggesting the potential of FtsZ as a drug target for antistaphylococcal therapy.","PeriodicalId":11325,"journal":{"name":"Drug news & perspectives","volume":"23 5","pages":"295-304"},"PeriodicalIF":0.0,"publicationDate":"2010-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"29102083","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 38

The future of epilepsy treatment: focus on adeno-associated virus vector gene therapy. 癫痫治疗的未来:关注腺相关病毒载体基因治疗。

Drug news & perspectives Pub Date : 2010-06-01 DOI: 10.1358/dnp.2010.23.5.1468393

Thomas J McCown

{"title":"The future of epilepsy treatment: focus on adeno-associated virus vector gene therapy.","authors":"Thomas J McCown","doi":"10.1358/dnp.2010.23.5.1468393","DOIUrl":"https://doi.org/10.1358/dnp.2010.23.5.1468393","url":null,"abstract":"Adeno-associated virus (AAV) vectors support long-term, nontoxic gene expression in the central nervous system, and these AAV properties prove particularly applicable to the treatment of focal epilepsies, especially intractable temporal lobe epilepsy. A number of clinical studies have employed AAV vectors and to date, no known adverse effects have been directly associated with these treatments, particularly AAV serotype 2 (AAV2). Although other AAV serotypes may confer an advantage in the future, extensive studies on the inhibitory neuropeptides, galanin and neuropeptide Y, have generated enough preclinical evidence of efficacy to warrant AAV2-based clinical trials in the near future. Beyond these trials, emerging evidence suggests that AAV-mediated manipulation of adenosine can significantly impact limbic seizure activity. Thus, with appropriate nonhuman primate transduction patterns and favorable overall toxicology studies, AAV-based manipulation of adenosine could follow the AAV-neuropeptide clinical studies. Finally, recent findings using AAV capsid shuffling and directed evolution have identified a hybrid AAV vector that can selectively cross the seizure compromised blood-brain barrier and transduce cells after peripheral, intravenous administration. Thus, in the more distant future, AAV therapeutics for focal epilepsies may be delivered without any neurosurgical interventions.","PeriodicalId":11325,"journal":{"name":"Drug news & perspectives","volume":"23 5","pages":"281-6"},"PeriodicalIF":0.0,"publicationDate":"2010-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"29102918","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 16

PRM-151 (recombinant human serum amyloid P/pentraxin 2) for the treatment of fibrosis. PRM-151(重组人血清淀粉样蛋白P/戊traxin 2)用于治疗纤维化。

Drug news & perspectives Pub Date : 2010-06-01 DOI: 10.1358/dnp.2010.23.5.1444206

Jeremy S Duffield, Mark L Lupher

引用次数: 74

CYBA gene variants as biomarkers for coronary artery disease. CYBA基因变异作为冠状动脉疾病的生物标志物

Drug news & perspectives Pub Date : 2010-06-01 DOI: 10.1358/dnp.2010.23.5.1437711

Maria U Moreno, Guillermo Zalba

{"title":"CYBA gene variants as biomarkers for coronary artery disease.","authors":"Maria U Moreno, Guillermo Zalba","doi":"10.1358/dnp.2010.23.5.1437711","DOIUrl":"https://doi.org/10.1358/dnp.2010.23.5.1437711","url":null,"abstract":"Oxidative stress plays a key role in the pathophysiology of coronary artery disease, and constitutes a common mechanism behind the risk factors associated with this disease such as atherosclerosis, hypertension, diabetes and the metabolic syndrome. Oxidative stress is defined as an imbalance between the production of reactive oxygen and nitrogen species and the detoxification by the appropriate cellular systems. Reactive oxygen species induce cardiovascular dysfunction by modulating cell contraction/dilation, migration, growth/apoptosis and extracellular matrix protein turnover, which contribute to vascular and cardiac remodeling. In the last decade, the NADPH oxidase family has emerged as one of the most relevant sources of reactive oxygen species within the cardiovascular system. Recent data suggest a significant role of the genetic background in NADPH oxidase regulation. Common genetic polymorphisms within the promoter and exonic sequences of CYBA, the gene that encodes the p22phox subunit of the NADPH oxidase, have been characterized in the context of cardiovascular diseases. This review aims to present the current state of research into these polymorphisms with regards to their relationship to coronary artery disease.","PeriodicalId":11325,"journal":{"name":"Drug news & perspectives","volume":"23 5","pages":"316-24"},"PeriodicalIF":0.0,"publicationDate":"2010-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"29102085","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 8

Quinpramine--a promising compound for treating immune-mediated demyelination of the nervous system. 喹丙嗪——一种治疗免疫介导的神经系统脱髓鞘的有前途的化合物。

Drug news & perspectives Pub Date : 2010-06-01 DOI: 10.1358/dnp.2010.23.5.1447850

Gerd Meyer zu Hörste, Anne K Mausberg, Carsten Korth, Olaf Stüve, Bernd C Kieseier

引用次数: 5

Pharmaceutical trademarks: navigating through the FDA's pilot program. 药品商标:通过FDA的试点计划导航。

Drug news & perspectives Pub Date : 2010-06-01 DOI: 10.1358/dnp.2010.23.5.1499108

Elisa Ferrer

引用次数: 0

The antipsychotic potential of muscarinic allosteric modulation. 毒蕈碱异构调节的抗精神病潜力。

Drug news & perspectives Pub Date : 2010-05-01 DOI: 10.1358/dnp.2010.23.4.1416977

Thomas M Bridges, Evan P LeBois, Corey R Hopkins, Michael R Wood, Carrie K Jones, P Jeffrey Conn, Craig W Lindsley

{"title":"The antipsychotic potential of muscarinic allosteric modulation.","authors":"Thomas M Bridges, Evan P LeBois, Corey R Hopkins, Michael R Wood, Carrie K Jones, P Jeffrey Conn, Craig W Lindsley","doi":"10.1358/dnp.2010.23.4.1416977","DOIUrl":"10.1358/dnp.2010.23.4.1416977","url":null,"abstract":"The cholinergic hypothesis of schizophrenia emerged over 50 years ago based on clinical observations with both anticholinergics and pan-muscarinic agonists. Not until the 1990s did the cholinergic hypothesis of schizophrenia receive renewed enthusiasm based on clinical data with xanomeline, a muscarinic acetylcholine receptor M(1)/M(4)-preferring orthosteric agonist. In a clinical trial with Alzheimer's patients, xanomeline not only improved cognitive performance, but also reduced psychotic behaviors. This encouraging data spurred a second clinical trial in schizophrenic patients, wherein xanomeline significantly improved the positive, negative and cognitive symptom clusters. However, the question remained: Was the antipsychotic efficacy due to activation of M(1), M(4) or both M(1)/M(4)? Classical orthosteric ligands lacked the muscarinic receptor subtype selectivity required to address this key question. More recently, functional assays have allowed for the discovery of ligands that bind at allosteric sites, binding sites distinct from the orthosteric (acetylcholine) site, which are structurally less conserved and thereby afford high levels of receptor subtype selectivity. Recently, allosteric ligands, with unprecedented selectivity for either M(1) or M(4), have been discovered and have demonstrated comparable efficacy to xanomeline in preclinical antipsychotic and cognition models. These data suggest that selective allosteric activation of either M(1) or M(4) has antipsychotic potential through distinct, yet complimentary mechanisms.","PeriodicalId":11325,"journal":{"name":"Drug news & perspectives","volume":"23 4","pages":"229-40"},"PeriodicalIF":0.0,"publicationDate":"2010-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4780339/pdf/nihms761222.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"29032149","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Peroxisome proliferator-activated receptor gamma agonists as neuroprotective agents. 过氧化物酶体增殖物激活受体激动剂作为神经保护剂。

Drug news & perspectives Pub Date : 2010-05-01 DOI: 10.1358/dnp.2010.23.4.1437710

Ravinder K Kaundal, Shyam S Sharma

{"title":"Peroxisome proliferator-activated receptor gamma agonists as neuroprotective agents.","authors":"Ravinder K Kaundal, Shyam S Sharma","doi":"10.1358/dnp.2010.23.4.1437710","DOIUrl":"https://doi.org/10.1358/dnp.2010.23.4.1437710","url":null,"abstract":"Peroxisome proliferator-activated receptor gamma (PPARgamma) has already been considered as an attractive therapeutic target for the treatment of metabolic disorders. Recently, PPARgamma agonists were shown to effectively attenuate oxidative stress, inflammation and apoptosis in the central nervous system. There are several preclinical and clinical studies indicating neuroprotective potential of PPARgamma agonists in the treatment of cerebral ischemia, Parkinson's disease, Alzheimer's disease, multiple sclerosis and amyotrophic lateral sclerosis. In these disorders, apart from inhibiting oxidative stress, inflammation and apoptosis, PPARgamma agonists have the potential to modulate various signaling molecules/pathways, including matrix metalloproteinase-9, mitogen-activated protein kinases, signal transducer and activator of transcription, mitochondrial uncoupling protein 2, mitoNEET expression, amyloid precursor protein degradation, beta-site amyloid precursor protein cleaving enzyme 1 and Wnt signaling. This article discusses evidence and mechanisms supporting the neuroprotective effects of PPARgamma agonists in central nervous system disorders.","PeriodicalId":11325,"journal":{"name":"Drug news & perspectives","volume":"23 4","pages":"241-56"},"PeriodicalIF":0.0,"publicationDate":"2010-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"29032150","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 66

Macrophage migration inhibitory factor (MIF): a promising biomarker. 巨噬细胞迁移抑制因子(MIF):一种有前景的生物标志物。

Drug news & perspectives Pub Date : 2010-05-01 DOI: 10.1358/dnp.2010.23.4.1453629

Gerrit Grieb, Melanie Merk, Jürgen Bernhagen, Richard Bucala

引用次数: 196

Immunotherapy for Epstein-Barr virus-associated malignancies. eb病毒相关恶性肿瘤的免疫治疗。

Drug news & perspectives Pub Date : 2010-05-01 DOI: 10.1358/dnp.2010.23.4.1439500

Heather M Long, Gregory Parsonage, Christopher P Fox, Steven P Lee

引用次数: 16